Topics

Selexis SA and Pelican Therapeutics Company Profile

09:39 EST 21st January 2020 | BioPortfolio

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 80+ drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.


News Articles [790 Associated News Articles listed on BioPortfolio]

Pelican Canada Appoints Managing Director

Ed Meyer to lead Pelican BioThermal’s global sales organization

ZyVersa, Selexis and KBI Enter Devt. and Mfg. Collaboration

To advance ZyVersa’s lead inflammasome inhibitor into clinic with Selexis and KBI’s integrated development platform

Avacta teams up with Selexis to develop Chinese hamster ovary cell line

On the tie-up with Selexis, Avacta chief executive Alastair Smith said the company's new partner provided “the technology and know-how” to develop the required cell lines for the planned first-in-...

Biotek Mini-Tek D Hard Case ALS Medic Case Pelican

$0.01 (0 Bids)End Date: Tuesday Jun-25-2019 13:43:26 PDTBid now | Add to watch list Biotech365 : Biotek Mini-Tek D Hard Case ALS Medic Case Pelican BioMarketplace You want to propose your product...

Selexis Appoints CBO

Yemi Onakunle will lead all corporate and business development activities

Generium Launches First Biosimilar of Dornase Alfa; Becomes Sixth Approved Product Using Selexis SUREtechnology Platform

Selexis SA and Generium JSC today announced that a sixth Selexis SUREtechnology Platform™-generated biological product has been approved for marketing. The latest approved product, dornase alfa inh...

Pelican BioThermal Achieves ISO Accreditation

Laboratories in the UK and US receive global recognition for technical capabilities and quality standards

Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

Selexis SA and Teneobio, Inc. announced today that they have signed three commercial license agreements (CLAs) for the development of Teneobio’s Human Heavy-Chain Antibodies (Un

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [419 Associated PubMed Articles listed on BioPortfolio]

Digital Therapeutics: Emerging New Therapy for Neurologic Deficits after Stroke.

Digital therapeutics is an evidence-based intervention using high-quality software, with the sole purpose of treatment. As many healthcare systems are encountering high demands of quality outcomes, th...

Measurement of mRNA therapeutics: method development and validation challenges.

The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for t...

Dr E. Keith Borden: Inaugural President of the Canadian Association for Population Therapeutics.

Pharmacovigilance 2030: Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and Therapeutics.

Metabolism: A Burning Opioid Issue in Obesity Therapeutics.

Food restriction triggers a lowering in body temperature. A new study now provides a mechanism for this process that relies on opioid signaling in the hypothalamus. These observations suggest potentia...

Clinical Trials [208 Associated Clinical Trials listed on BioPortfolio]

Effectiveness of the Pelican Instrument in Medical Care

The objective of this project is to establish the effectiveness of implementation of a self-administered electronic asthma-specific quality of life instrument for childhood asthma in prima...

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Companies [1432 Associated Companies listed on BioPortfolio]

Selexis SA and Pelican Therapeutics

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology a...

Selexis SA

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs ...

Selexis SA and Hoba Therapeutics

Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly d...

Pelican Products, Inc.

Pelican Products, Inc. is the global leader in design and manufacture of both high-performance protective case solutions and advanced portable LED lighting systems. Their produ...

Selexis SA and Berkeley Lights, Inc.

Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly d...

More Information about "Selexis SA and Pelican Therapeutics" on BioPortfolio

We have published hundreds of Selexis SA and Pelican Therapeutics news stories on BioPortfolio along with dozens of Selexis SA and Pelican Therapeutics Clinical Trials and PubMed Articles about Selexis SA and Pelican Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Selexis SA and Pelican Therapeutics Companies in our database. You can also find out about relevant Selexis SA and Pelican Therapeutics Drugs and Medications on this site too.

Quick Search

Relevant Topic

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...


Corporate Database Quicklinks



Searches Linking to this Company Record